A Phase II, Randomised, Double Blind Study Assessing the Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia.
Phase of Trial: Phase II
Latest Information Update: 20 May 2013
At a glance
- Drugs EGb 761 (Primary)
- Indications Friedreich's ataxia
- Focus Therapeutic Use
- 21 Jun 2012 Company added in the association field as reported by ClinicalTrials.gov.
- 29 Nov 2011 Actual patient number is 22 according to ClinicalTrials.gov.
- 29 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.